An investment bank based in the US actively seeks new investment opportunities. The firm does not act as a traditional investment bank, as they participate in venture capital, investing in and working with early-stage technology and life science companies with the main goal of taking the companies to public market. The firm generally does not look at digital health. The firm has also spun out and out-licensed technologies from universities and has capabilities to help with company formation, business strategy, IP, and early IPOs. The firm utilizes their sister company to further analyze company technologies and IPs. The firm can fund from $5M-12M USD from Seed to Series A rounds with preference in US-based companies, though open to global companies. 
 
The firm is looking at biotech, medical devices, and diagnostics companies and is technology-agnostic. The firm generally does not look at digital health. There has been strong interest in immuno-oncology, neurology, and CNS. 
 
The firm works closely with companies and founder and will lead investment rounds. The firm typically requires taking a board or observer seat while deciding strategy, and once the company goes public, the firm will bring in a board member with expertise in the field. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

A venture builder and fund is looking to invest in US-based neurotechnology device companies advancing transformative diagnostics and therapies. The firm offers 3 different opportunities to support companies: (1) grants to academic researchers whose research aligns with the firm’s interests, (2) venture creation where the firm helps founders create, augment, and support companies, and (3) traditional equity investing. The firm engages in Pre-Seed to Series A rounds with typical check sizes ranging from $250k-2M USD. 
 
The firm primarily invests in medical devices that address stress and anxiety, sleep, and pain. The firm is open to working with companies from in-development stages. The firm is also open to take a leap on long-shot technologies that have potential to make significant changes in the neurotechnology space. 
 
The firm does not have specific management team requirements and typically does not lead. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   
 

Founded in 2010, with headquarters in Shanghai (China) and additional operations in USA, a global biopharmaceutical company has a vision to offer high-quality, affordable, and innovative biologic medicines for patients worldwide with a focus on oncology and immunology. The firm has launched 5 products in China, 1 in overseas markets (including EU) during past 4 years. 
 
The firm is seeking to in-license innovative assets and platforms in oncology that have synergies with the company’s current portfolio, in addition to seeking development and commercial partners for our oncology programs. 

The firm has no specific requirements. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

A venture capital firm headquartered in Western Europe invests in healthcare companies with typical check size ranging from €1-20M EUR, participating starting from the 2nd or 3rd rounds of financing until Series B. The firm focuses on companies in the U.S. or Europe. 
 
The firm invests in diagnostics, digital health, and medical devices. The firm does not invest in drugs, biotech, or therapeutics. The firm invests in companies in the in-development or clinical stages. The firm is indication-agnostic. 
 
The firm does not have specific management team requirements. The firm typically takes a board or observer seat on a case-by-case basis. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

An investment vehicle of a world-class CDMO partner from concept to commercialization is looking for partnerships with cell and gene therapy related pipelines companies in Pre-Seed or Series A rounds with typical check sizes ranging from $500k-2M USD. The fund is open to global companies though prefers US-based companies. 
 
The firm is solely interested in cell and gene therapy related pipeline companies. The fund is indication-agnostic and is open to orphan diseases as well. Companies should be pre-IND and must have proof of concept. 
 
The firm may take a board or observer seat on a case-by-case basis. The fund requires founders to be full-time. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   
 

A venture capital firm founded in 2021 with headquarters in the US engages in Seed to Series C rounds, with preference in Series A-C, and focuses on solutions towards a variety of unmet medical needs. The firm is interested in precise, personalized and cost-effective medical technologies and services. While opportunistic regarding sectors, the firm has invested in companies including therapeutics, medtech, diagnostics, and digital health. Typical check sizes range from $3-7M USD on entry with some reserved for follow-ons. The firm can lead investments as well as join syndicates. Although U.S. companies are favored, the firm can invest globally. 
 
The firm is opportunistic in terms of life science and healthcare companies. The firm has a strong focus on ophthalmology, neurology, and pulmonology. For software, the firm has deep ties to the hospital innovation system and looks for opportunities that intersect the patient-provider interface. 
 
The firm typically requires taking a board or observer seat. The firm does not have specific company or management team requirements. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

A VC invests in US and Canada-based companies. The firm will generally participate in Series A financing rounds and beyond, including crossover and IPO; average check sizes will be around $5-10M CAD, with a total of $15-20M CAD will be reserved for follow-on investments. In addition, the firm is also dedicated to company incubation and creation for which the firm will work with earlier stage companies and deploy smaller amounts of capital (around $1M CAD). 
 
The firm has a general theme of investing in precision medicine – technologies that can enhance the quality and accuracy of diagnoses, enable more precise and personalized treatments, targeted therapies such as cell & gene therapy, technologies that leverage AI to accelerate therapeutic development, etc. In terms of sector, the firm seeks to invest 50-60% in therapeutics, 20-30% in medical devices, and 10-15% in AI/digital health/diagnostics. For medical devices, the firm prefers later stage opportunities that are close to commercialization. The firm does not focus on any particular indication area. 
 
The firm does not have specific company or management team requirements. While the firm likes to see management teams with a successful track record and wide range of experiences, this is not required and the firm is open to working on inexperienced management teams. The firm is capable of leading or co-leading investment rounds, and is also open to co-investing with likeminded investors. The firm is very hands-on and leverages their network to actively support the growth of their portfolio companies and provide needed resources. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.